EVALUATION OF A HAEMOSTATIC AGENT IN RABBITS

Topical hemostatic agents are applied locally to areas of injured vascular endothelium to control local bleeding. Ankaferd Blood Stopper (ABS) has gained approval in Turkey and Bosnia-Herzegovina as a topical haemostatic agent for external post-surgical and post-dental surgery bleeding. The safety of topical use of ABS has been demonstrated in numerous in vitro and in vivo animal models, as well as in a clinical Phase I trial in humans. ABS, besides its haemostatic activity, also has in vitro anti-infectious and anti-neoplastic effects. To assess potential detrimental effects of intravenous administration of ABS into intact systemic circulation in a rabbit experimental model, one milliliter of ABS was administered intravenously into the systemic circulation of twelve rabbits which were included in the study via the marginal ear vein. Animals were observed for 1 hr before euthanasia was performed by administering 40 mg of intracardiac suxamethonium chloride. In the event of death (cardiopulmonary arrest) before the end of the planned observation period of 60 minutes, time of death was recorded and histopathological examination of the liver and spleen was commenced. Ten rabbits were alive by the end of the planned observation period, without showing any clear signs of discomfort, whereas two animals died within five minutes after systemic administration of intravenous ABS. Postmortem histopathological examination of the livers and spleens of all animals’ revealed findings consistent with hepatic venous outflow obstruction. Systemic intravascular administration of ABS into intact vascular endothelium should never be performed in any setting. Further experimental and clinical studies on this liquid hemostatic agent should proceed by accepting ABS as purely a topical haemostatic agent, to be applied solely to areas of injured vascular endothelium

Treatment of radius-ulna and tibia fractures with circular external skeletal fixator in 19 dogs

WOS: 000251789800004PubMed: 18198537This study was carried out on 19 dogs of different breed, age and sex. 10 different types of radius-ulna and 9 tibia fractures were treated by circular external skeletal fixator. The cases were followed by clinical and radiological controls in the postoperative period. It was observed that the cases tolerated the apparatus well. There was no looseness of fixator stability and configuration during the 15-day interval examination. Complications like pin track, serous drainage and pin loosening were observed postoperatively. It was concluded that radiographic, clinical and anatomical data together with good preoperative planning, the Ilizarov Method and circular external skeletal fixator was successful for the treatment of open or closed fragmented radius-ulna and tibia fractures in dogs

Unifocal internal and external bone lengthening with circular external skeletal fixator in 5 dogs

WOS: 000256958800013PubMed: 18683547The purpose of this study was to investigate the effectiveness of treatment of long bone defects and extremity shortness in 5 dogs using circular external skeletal fixator. In one case a bone necrosis and osteomyelitis shortened radius by 7.0 cm; however in others extremity shortening between 3.0 and 6.0 cm affected radius-ulna or tibia. 2 or 3 rings of 80.0-100.0 mm diameters, and 3 rods were used as a circular external skeletal fixator. The distractions at the rate of 0.5 mm X 2 times/day were performed following a latent period of 3 days after the corticotomy. Unifocal internal lengthening for case 1 and unifocal external lengthening for the others were performed. Distraction was performed between 30 and 70 days (mean 50 days). It was noted that the circular external skeletal fixator was well-tolerated in all cases. The first usages of limbs in all cases were on postoperative day between 8 and 43 (mean 22 days). The radiographic follow-up examinations revealed a complete consolidation on postoperative day between 35 and 75 (mean 55.6 days). The fixators were removed on the postoperative day between 45 and 85 (mean 65 days). The treatment was successful in restoring the appropriate length of the limbs. After removing the fixator, functional and cosmetic results were graded as excellent in 3 cases, good in one case and fair in one case

In vitro and in vivo evaluation of the effects of demineralized bone matrix or calcium sulfate addition to polycaprolactone-bioglass composites

The objective of this study was to improve the efficacy of polycaprolactone/bioglass (PCL/BG) bone substitute using demineralized bone matrix (DBM) or calcium sulfate (CS) as a third component. Composite discs involving either DBM or CS were prepared by compression moulding. Bioactivity of discs was evaluated by energy dispersive X-ray spectroscopy (ESCA) and scanning electron microscopy (SEM) following simulated body fluid incubation. The closest Calcium/Phosphate ratio to that of hydroxyl carbonate apatite crystals was observed for PCL/BG/DBM group (1.53) after 15 day incubation. Addition of fillers increased microhardness and compressive modulus of discs. However, after 4 and 6-week PBS incubations, PCL/BG/DBM discs showed significant decrease in modulus (from 266.23 to 54.04 and 33.45 MPa, respectively) in parallel with its highest water uptakes (36.3 and 34.7%). Discs preserved their integrity with only considerable weight loss (7.5-14.5%) in PCL/BG/DBM group. In vitro cytotoxicity tests showed that all discs were biocompatible. Composites were implanted to defects on rabbit humeri. After 7 weeks, new tissue formation and mineralization at bone-implant interface were observed for all implants. Bone mineral densities at interface were higher than that of implant site and negative controls (defects left empty) but lower than healthy bone level. However, microhardness of implant sites was higher than in vitro results indicating in vivo mineralization of implants. Addition of DBM or CS resulted with higher microhardness values at interface region (ca. 650 mu m from implant) compared to PCL/BG and negative control. Histological studies revealed that addition of DBM enhanced bone formation around and into implant while CS provided cartilage tissue formation around the implant. From these results, addition of DBM or CS could be suggested to improve bone healing efficacy of PCL/BG composites

Oral Systemic Administration Of Ankaferd Blood Stopper Has No Short-Term Toxicity In An In Vivo Rabbit Experimental Model

Scopu